Smith+Nephew Announces Commercial Launch Of Its AETOS Shoulder System For Anatomic And Reverse Shoulder Replacement At AAOS 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Smith+Nephew (NYSE:SNN) announced the full commercial launch of its AETOS Shoulder System in the US, following FDA 510(k) clearance. This system, designed for both anatomic and reverse shoulder replacement, aims to restore range-of-motion and minimize arthritic pain. It features the Meta Stem for stability and bone preservation. The system is complemented by ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation, developed in partnership with Materialise NV, for pre-operative planning. This launch is significant in the rapidly growing total shoulder arthroplasty market, expected to reach 250,000 procedures in the US by 2025.
February 13, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Smith+Nephew's launch of the AETOS Shoulder System, with FDA 510(k) clearance, positions the company to capitalize on the growing total shoulder arthroplasty market. The system's innovative design and partnership with Materialise NV for pre-operative planning software could enhance SNN's product portfolio and market share in orthopaedics.
The AETOS Shoulder System addresses a rapidly growing segment in orthopaedics, with an estimated 250,000 procedures expected in the US by 2025. The system's innovative features and the strategic partnership for pre-operative planning software not only enhance Smith+Nephew's product offering but also position the company to meet the increasing demand for shoulder arthroplasty solutions. This launch is likely to have a positive short-term impact on SNN's stock price as it demonstrates the company's commitment to innovation and growth in the orthopaedic market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100